By Fineline Cube 
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received clinical clearance from the National Medical Products Administration (NMPA) for its HRS-9821 inhalation powder. This development marks a significant step forward in the treatment of chronic obstructive pulmonary disease (COPD).
Drug Mechanism
HRS-9821 is a small-molecule dual inhibitor targeting PDE3 and PDE4 enzymes. It effectively suppresses airway inflammation and induces bronchodilation, making it suitable for the maintenance treatment of COPD. By inhibiting these enzymes, HRS-9821 helps reduce inflammation and relaxes the muscles around the airways, improving breathing in patients with COPD.
Market Context
Currently, Ensifentrine, which gained approval in the U.S. in July 2024, is the sole marketed drug in this class for COPD maintenance therapy. HRS-9821 has the potential to offer an additional treatment option for patients suffering from this chronic respiratory condition.-Fineline Info & Tech